AptarGroup Full Year 2024 Earnings: EPS Beats Expectations

AptarGroup (NYSE:ATR) Full Year 2024 Results

Key Financial Results

• Revenue: US$3.58b (up 2.7% from FY 2023).
• Net income: US$374.5m (up 32% from FY 2023).
• Profit margin: 11% (up from 8.2% in FY 2023).
• EPS: US$5.65 (up from US$4.34 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

AptarGroup EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.8%.

The primary driver behind last 12 months revenue was the Aptar Pharma segment contributing a total revenue of US$1.64b (46% of total revenue). Notably, cost of sales worth US$2.23b amounted to 62% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$582.2m (59% of total expenses). Explore how ATR's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Packaging industry in the US.

Performance of the American Packaging industry.

The company's shares are down 8.9% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on AptarGroup's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.